In a bold move that straddles the cutting edge of longevity science and the murky waters of marketing, a startup named Generation Lab has announced a revolutionary rejuvenation treatment, dubbed "1 Generation." This injectable concoction, composed of two existing, undisclosed drugs, purports to fundamentally reverse the aging process at a cellular level, offering a tantalizing glimpse into a future where biological youth is attainable. The company’s claims are audacious: to "block the systemic spread of aging in the bloodstream, reawaken the body’s own repair mechanism, and restore health and youth to multiple tissues." This ambitious assertion has already garnered significant attention, with the company reportedly extending exclusive invitations to a "private cohort" of individuals whose judgment they trust, under strict medical supervision, and facing a substantial waiting list that includes notable public figures and celebrities.

Alina Su, Generation Lab’s 26-year-old CEO, enthusiastically described the treatment during a conference call, stating, "This first longevity therapeutic in the human body is here and it’s actually working." While the marketing campaign is undeniable, and the claims, as with many in the longevity field, invite skepticism, the underlying science is rooted in the pioneering work of Generation Lab’s irascible scientific founder, Dr. Irina Conboy. Dr. Conboy, a distinguished specialist in parabiosis, or heterochronic blood exchange, has a long and respected career exploring the profound effects of blood transfer between young and old animals. Parabiosis is one of the few experimentally proven methods to demonstrably rejuvenate aged animals, making them behave and function with the vitality of their younger counterparts.

The challenge, however, has always been translating this laboratory success into a practical human therapy. The idea of surgically connecting individuals to share circulatory systems is, understandably, not a viable long-term solution. This is where Conboy’s latest breakthrough comes into play. She claims to have identified a specific combination of two existing drugs that can mimic the rejuvenating effects of parabiosis without the need for any invasive bodily fluid exchange. Conboy herself has been part of an early group of insiders, including Su, her husband and collaborator Michael Conboy, and a handful of other individuals, who have been undergoing the treatment for the past two months. They report feeling significantly better, more energetic, and experiencing a range of improvements.

The reported benefits, detailed in a spreadsheet shared by Generation Lab’s public relations team, are diverse and, frankly, astonishing. They include improved vision in a 64-year-old participant, extended periods of physical activity like landscaping and badminton for a 59-year-old man, enhanced hand grip, and even claims of superior erectile function compared to Viagra, alongside "increased bowel movements." While the prospect of an age-reversal drug that delivers such a broad spectrum of benefits is undeniably alluring, the scientific community remains cautious, a sentiment echoed by the author’s own initial assessment that the proposition is "probably too good to be true," especially given Generation Lab’s reluctance to disclose the identity of the two drugs.

However, the allure of Dr. Conboy’s established scientific reputation and her groundbreaking research in parabiosis provides a compelling reason to delve deeper. Her work at the University of California, Berkeley, particularly a seminal 2005 study published in Nature, demonstrated that surgically connecting young and old mice led to a dramatic improvement in the aged animals’ ability to heal from injuries. This research strongly suggested that young blood carries powerful molecular signals capable of restoring regenerative capacity in older organisms. This revelation spurred the development of several startups, including Elevian and Alkahest, which have secured significant funding to pursue treatments for conditions like stroke and Alzheimer’s, though commercial success has remained elusive.

The understanding that young blood benefits older animals is coupled with the knowledge that the reverse is also true: aged blood can have detrimental effects on younger ones. Conboy aptly summarizes this dynamic, stating that in the battle of age versus youth, "old blood dominates." This led her to explore a novel approach. In 2020, she investigated removing aged plasma and replacing it with a neutral mixture of albumin and salt water, effectively "deleting" the detrimental molecules associated with aging. This "reset" procedure yielded even more potent rejuvenating effects than heterochronic blood exchange and was subsequently tested on human volunteers who underwent a significant portion of their blood volume replacement.

The longevity clinic landscape has been quick to embrace Conboy’s research, with some offering "therapeutic plasma exchange" as a wellness intervention, commanding prices as high as $10,000 per session. Dr. Jeffrey Gladden, a proponent of this procedure, was so impressed by Conboy’s publications that he traveled to California to meet her and undergo the treatment himself. By the end of 2025, Dr. Conboy had transitioned from Berkeley to lead Generation Lab full-time. While the company had been selling an aging diagnostic test, Conboy remained driven to find a drug that could replicate the benefits of plasma exchange. This pursuit led her to utilize a novel testing system she co-developed. This system allows researchers to expose human cells in a microfluidic device to blood serum from older individuals, facilitating rapid testing of her hypotheses about potential drug candidates.

Described in a recent publication, this innovative device enables scientists to address a crucial question: "If tissue becomes old in the presence of old blood, which molecule or combination of molecules will prevent that and allow tissue to remain young, even when the circulatory milieu is old?" Conboy asserts that "1 Generation" achieves this by simultaneously stimulating cellular regeneration and neutralizing age-associated factors in the bloodstream, enabling human cells to maintain their youthful characteristics even in the presence of aged blood serum.

Despite the compelling scientific foundation, the proprietary nature of the drug combination fuels legitimate questions. Without knowing the specific agents involved, offering a definitive opinion on their potential is impossible. However, some physicians associated with Generation Lab have expressed surprise at the purported efficacy of the drug. Dr. Gladden, whose Texas clinic will participate in the upcoming study, candidly stated, "I will say right now, candidly, it’s an unknown how it will play out. But there’s certainly a lot of enthusiasm based on the quality of her work in the past." He described his stance as "skeptical and optimistic at the same time."

When pressed on the secrecy surrounding the drug names, CEO Alina Su explained that it is a strategic move to preempt imitators, as Generation Lab does not possess patents for these molecules. Their strategy involves a swift clinical trial, leveraging an FDA process that grants a limited period of exclusivity, potentially three years, for demonstrating a novel therapeutic use of existing drugs.

In the interim, Generation Lab’s efforts to generate buzz are proving successful. An exclusive, invite-only event scheduled for August 28 will feature prominent figures such as George Church, a renowned synthetic biologist from Harvard University, and researchers from Anthropic, a company whose CEO, Dario Amodei, has made predictions about AI eradicating all diseases within a few years. Dr. Church himself confirmed he was offered the opportunity to participate in the drug trial. The demand for this treatment is palpable, with Dr. Cook of BioReset Medical reporting a surge in inquiries from "high-end doctors, venture capitalists, and people in this community who are kind of biohackers," describing them as "high-level influencer-type people."

For the author, however, the decision to partake in the treatment remains on hold. The commitment to transparency in scientific reporting necessitates a clear understanding of the underlying components. As a correction to a previous version of this story noted, while patients may have options to access the drug through physicians, the larger clinical trial will be free for participants and fully sponsored by Generation Lab, a crucial clarification in the ongoing narrative.